ArticleAuto- immunity highlights2015
Decreased serum cell-free DNA levels in rheumatoid arthritis.
Article in Auto- immunity highlights, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Plasma circulating free DNA in chronic schizophrenia: a case-control study.Scientific reports · 2026Article
- Cell-Free DNA-Based Theranostics for Inflammatory Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- NETosis-Related Biomarkers in Systemic Lupus Erythematosus, Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis: A Comparative Study.International journal of molecular sciences · 2025Article
- Cell-free DNA: a metabolic byproduct with diagnostic and prognostic potential in rheumatic disorders.Frontiers in pharmacology · 2025Review
- Plasma mtDNA as a possible contributor to and biomarker of inflammation in rheumatoid arthritis.Arthritis research & therapy · 2024Observational
- Naïve Inflammatory Proteome Profiles of Glucocorticoid Responsive Polymyalgia Rheumatica and Rheumatic Arthritis Patients-Links to Triggers and Proteomic Manifestations.Journal of personalized medicine · 2024Article
- Circulating cell-free DNA correlate to disease activity and treatment response of patients with radiographic axial spondyloarthritis.Scientific reports · 2024Article
- The role of Extracellular Genomic Materials (EGMs) in psychiatric disorders.Translational psychiatry · 2023Review
- Role of Liquid Biopsies in Rheumatoid Arthritis.Methods in molecular biology (Clifton, N.J.) · 2023Review
- The dynamics of extracellular DNA associates with treatment response in patients with rheumatoid arthritis.Scientific reports · 2022Article
- Cell-Free DNA in the Pathogenesis and Therapy of Non-Infectious Inflammations and Tumors.Biomedicines · 2022Review
- The protein corona modulates the inflammation inhibition by cationic nanoparticlesBioactive materials · 2022Article
- Cell-Free DNA in Rheumatoid Arthritis.International journal of molecular sciences · 2021Review
- Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms.International journal of molecular sciences · 2020Review
- The Impact of Pre-transplant Cell-free DNA Levels on Leukemia Relapse and Transplant-related Complications in Allogeneic Hematopoietic Stem Cell Transplant RecipientsBalkan medical journal · 2020Article
- Identification of Specific Joint-Inflammatogenic Cell-Free DNA Molecules From Synovial Fluids of Patients With Rheumatoid Arthritis.Frontiers in immunology · 2020Article
- Considerations and quality controls when analyzing cell-free tumor DNA.Biomolecular detection and quantification · 2019Article
- Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases.Frontiers in immunology · 2019Review
- Liquid biopsies to guide therapeutic decisions in rheumatoid arthritis.Translational research : the journal of laboratory and clinical medicine · 2018Review
- Anti-cytokine therapy and plasma DNA in patients with rheumatoid arthritis.Rheumatology international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecent studies have demonstrated that serum/plasma DNA and RNA molecules in addition to proteins can serve as biomarkers. Elevated levels of these nucleic acids have been found not only in acute, but also in chronic conditions, including autoimmune diseases. The aim of this study was to assess cell-free DNA (cfDNA) levels in sera of rheumatoid arthritis (RA) patients compared to controls.
methodscfDNA was extracted from sera of patients with early and established RA, relapsing-remitting multiple sclerosis patients (RRMS) and healthy subjects, and its concentration was determined by quantitative PCR using two amplicons, Alu115 and β-actin205, corresponding to Alu repetitive elements and the β-actin single-copy gene, respectively. Serum DNase activity was measured by a single radial enzyme diffusion method.
resultsReduced levels of cfDNA were observed in patients with established RA in comparison with healthy controls, early RA patients and RRMS patients. There were no significant differences in cfDNA concentration between healthy controls, early RA and RRMS patients. Total DNase activity appeared to be similar in the sera of all tested groups.
conclusionsOur results demonstrate that cfDNA levels are strongly reduced in the sera of established RA patients, which is not caused by changes in DNase activity. Measurement of cfDNA can distinguish established RA patients from early RA patients. Thus, cfDNA may serve as a biomarker in RA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.